Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility

C. Roland Wolf, C. A.Dale Smith, Alan C. Gough, Julie E. Moss, Katherine A. Vallis, Graham Howard, Frank J. Carey, Ken Mills, William Mcnee, James Carmichael, Nigel K. Spurr

    Research output: Contribution to journalArticlepeer-review

    139 Citations (Scopus)


    There have been a series of reports on the association of a genetic polymorphism at the cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many of these reports have remained contradictory either because of small numbers of patients studied or because of the limitations and controversy surrounding the pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We have recently developed a DNA-based assay that will allow the unequivocal identification of poor metabolizers and have applied this to the study of 1635 patients with different forms of cancer. Out of 361 lung cancer patients studied no statistically significant change in the proportion of PMs relative to controls was found. However, a significant increase in the proportion of poor metabolizers or heterozygotes was seen in leukaemia, bladder cancer and melanoma patients. This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.

    Original languageEnglish
    Pages (from-to)1035-1038
    Number of pages4
    Issue number6
    Publication statusPublished - 1 Jun 1992

    ASJC Scopus subject areas

    • Cancer Research


    Dive into the research topics of 'Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility'. Together they form a unique fingerprint.

    Cite this